PCL moves were not uniform
PCL fell at BMO, Scotiabank, CIBC and TD, and rose at NBC and RBC.
A curated six-bank view designed for a fast, evidence-aware read.
Quarterly PCL fell at four banks, but compatible impaired-exposure and reserve signals remained mixed.
PCL fell at BMO, Scotiabank, CIBC and TD, and rose at NBC and RBC.
RBC GIL rose CAD 353 million and impaired PCL rose CAD 80 million; impaired ACL fell CAD 93 million.
CIBC total PCL fell CAD 41 million: performing PCL fell CAD 105 million while impaired PCL rose CAD 64 million.
TD GIL fell CAD 138 million and impaired PCL fell CAD 108 million; Stage 2 ACL rose CAD 50 million.
Direct values and bounded review classes; not a bank ranking.
| Bank | Exposure | Provision | Reserve | Attention |
|---|---|---|---|---|
| Bank of Montreal | GIL CAD 6,803m; -136m QoQ | PCL CAD 722m; -17m QoQ | Stage 3 CAD 1,268m; +107m QoQ | watch |
| Scotiabank | GIL CAD 7,801m; +193m QoQ | PCL CAD 1,079m; -138m QoQ | Stage 3 CAD 2,498m; +90m QoQ | watch |
| CIBC | GIL CAD 4,024m; +57m QoQ | PCL CAD 564m; -41m QoQ | Stage 3 CAD 1,204m; +154m QoQ | elevated attention |
| National Bank of Canada | GIL CAD 4,031m; Comparison unavailable: scope changed | PCL CAD 246m; +13m QoQ | Stage 3 CAD 1,026m; +90m QoQ | watch |
| Royal Bank of Canada | GIL CAD 10,143m; +353m QoQ | PCL CAD 1,000m; +88m QoQ | Stage 3 CAD 2,224m; -93m QoQ | routine |
| TD Bank Group | GIL CAD 5,143m; -138m QoQ | PCL CAD 917m; -84m QoQ | Stage 3 CAD 1,443m; -87m QoQ | watch |
Move from the headline to three verified movements and the current evidence limitation.
GIL: CAD 6,803m; -136m QoQ
IMPAIRED PCL: CAD 708m; -26m QoQ
IMPAIRED ACL: CAD 1,268m; +107m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
The public demo is a curated subset. The private workspace adds full history, portfolio detail, evidence drilldown, review workflows, deeper Q&A, and an analyst memo.
FY2026 Q3 versus Q2; composition retains each bank's disclosed perimeter.
Current and prior quarter are direct, duration-compatible statement facts.
| Bank | Q2 PCL | Q3 PCL | Change | QoQ | Scope |
|---|---|---|---|---|---|
| Bank of Montreal | CAD 739m | CAD 722m | -17 | -2.3% | Consolidated PCL |
| Scotiabank | CAD 1,217m | CAD 1,079m | -138 | -11.3% | Consolidated PCL |
| CIBC | CAD 605m | CAD 564m | -41 | -6.8% | Consolidated PCL |
| National Bank of Canada | CAD 233m | CAD 246m | +13 | +5.6% | Consolidated PCL |
| Royal Bank of Canada | CAD 912m | CAD 1,000m | +88 | +9.6% | Consolidated PCL |
| TD Bank Group | CAD 1,001m | CAD 917m | -84 | -8.4% | Consolidated PCL |
Peer views compare only compatible metrics and do not rank credit quality or reserve adequacy.
The peer median describes QoQ PCL percentage change, not bank risk.
| Bank | QoQ PCL | Peer median | Position | Scope |
|---|---|---|---|---|
| Bank of Montreal | -2.3% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
| Scotiabank | -11.3% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
| CIBC | -6.8% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
| National Bank of Canada | +5.6% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
| Royal Bank of Canada | +9.6% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
| TD Bank Group | -8.4% | -4.5% | Descriptive movement, not risk rank | Consolidated statement PCL, not a like-for-like portfolio-loss-rate comparison |
How the curated public subset is selected and constrained.
The same financial semantics govern both workspace modes.
CAD millions; quarterly flows and ending stocks remain distinct. Comparisons require reviewed scope and duration, not matching metric names.
QoQ percentage change in consolidated statement PCL. Each bank's own approved FY2026 Q2 consolidated PCL; not gross loans
No missing disclosure is inferred and no compatible series is extended across a break.
Bank of Montreal FY2026 Q3 Report to Shareholders
Bank of Montreal FY2026 Q3 Supplemental Financial Information
Scotiabank FY2026 Q3 Report to Shareholders
Scotiabank FY2026 Q3 Supplemental Financial Information
CIBC FY2026 Q3 Report to Shareholders
National Bank of Canada FY2026 Q3 Report to Shareholders
Royal Bank of Canada FY2026 Q3 Report to Shareholders
TD Bank Group FY2026 Q3 Report to Shareholders
Bank of Montreal FY2026 Q2 Approved PCL Stack release
Scotiabank FY2026 Q2 Approved PCL Stack release
CIBC FY2026 Q2 Approved PCL Stack release
National Bank of Canada FY2026 Q2 Approved PCL Stack release
Royal Bank of Canada FY2026 Q2 Approved PCL Stack release
TD Bank Group FY2026 Q2 Approved PCL Stack release
GIL: CAD 6,803m; -136m QoQ
IMPAIRED PCL: CAD 708m; -26m QoQ
IMPAIRED ACL: CAD 1,268m; +107m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
GIL and impaired PCL fell; Stage 3 ACL increased.
GIL: CAD 6,803m; -136m QoQ
IMPAIRED PCL: CAD 708m; -26m QoQ
IMPAIRED ACL: CAD 1,268m; +107m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2024-Q3 | CAD 6,041m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2024-Q4 | CAD 5,843m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2025-Q1 | CAD 6,954m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2025-Q2 | CAD 6,739m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2025-Q3 | CAD 6,951m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2025-Q4 | CAD 7,091m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q1 | CAD 6,863m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q2 | CAD 6,939m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 6,803m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 1,474m | CAD 1,378m | Total ACL on loans and other credit instruments | compatible |
| STAGE 2 ACL | CAD 3,288m | CAD 3,259m | Total ACL on loans and other credit instruments | compatible |
| STAGE 3 ACL | CAD 1,268m | CAD 1,161m | Total ACL on loans and other credit instruments | compatible |
| NON IMPAIRED ACL | CAD 4,762m | CAD 4,637m | Total ACL on loans and other credit instruments | compatible |
| IMPAIRED ACL | CAD 1,268m | CAD 1,161m | Total ACL on loans and other credit instruments | compatible |
| TOTAL ACL | CAD 6,030m | CAD 5,798m | Total ACL on loans and other credit instruments | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
BMO attributes the quarterly decline in impaired PCL largely to lower Canadian P&C provisions. BMO attributes the quarterly GIL decline largely to lower impaired loans in Capital Markets.
Direct explanation
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD 14m | CAD 708m | CAD 722m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -683 | Disclosed component; no causal claim |
| recoveries | +173 | Disclosed component; no causal claim |
| other fx | +16 | Disclosed component; no causal claim |
| pcl | +726 | Disclosed component; no causal claim |
Loans and other credit instruments. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
GIL: CAD 7,801m; +193m QoQ
IMPAIRED PCL: CAD 1,018m; -111m QoQ
IMPAIRED ACL: CAD 2,498m; +90m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
GIL rose while impaired PCL fell.
GIL: CAD 7,801m; +193m QoQ
IMPAIRED PCL: CAD 1,018m; -111m QoQ
IMPAIRED ACL: CAD 2,498m; +90m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2025-Q3 | CAD 6,890m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2025-Q4 | CAD 7,244m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q1 | CAD 7,248m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q2 | CAD 7,608m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 7,801m | Gross loans and acceptances | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 1,783m | CAD 1,702m | ACL on funded loans only | compatible |
| STAGE 2 ACL | CAD 3,048m | CAD 3,040m | ACL on funded loans only | compatible |
| STAGE 3 ACL | CAD 2,498m | CAD 2,408m | ACL on funded loans only | compatible |
| NON IMPAIRED ACL | CAD 4,831m | CAD 4,742m | ACL on funded loans only | compatible |
| IMPAIRED ACL | CAD 2,498m | CAD 2,408m | ACL on funded loans only | compatible |
| TOTAL ACL | CAD 7,329m | CAD 7,150m | ACL on funded loans only | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
Scotiabank attributes lower quarterly impaired PCL primarily to the Canadian retail and International corporate portfolios. Scotiabank attributes higher GIL primarily to currency translation and new formations in Canadian Banking and International retail. Scotiabank links higher impaired-loan ACL to corporate and International retail provisions and currency translation.
Direct explanation
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD 61m | CAD 1,018m | CAD 1,079m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -1,083 | Disclosed component; no causal claim |
| recoveries | +146 | Disclosed component; no causal claim |
| other fx | +76 | Disclosed component; no causal claim |
| pcl | +1,067 | Disclosed component; no causal claim |
Loans and off-balance-sheet commitments, excluding debt securities. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
GIL: CAD 4,024m; +57m QoQ
IMPAIRED PCL: CAD 612m; +64m QoQ
IMPAIRED ACL: CAD 1,204m; +154m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
Total PCL fell despite higher impaired PCL and GIL.
GIL: CAD 4,024m; +57m QoQ
IMPAIRED PCL: CAD 612m; +64m QoQ
IMPAIRED ACL: CAD 1,204m; +154m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2025-Q3 | CAD 3,281m | Impaired loans, consumer and business/government | Same disclosed table and scope; no cross-source join. |
| FY2026-Q2 | CAD 3,967m | Impaired loans, consumer and business/government | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 4,024m | Impaired loans, consumer and business/government | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 1,080m | CAD 1,038m | Total ECL on loans and undrawn commitments | compatible |
| STAGE 2 ACL | CAD 2,699m | CAD 2,782m | Total ECL on loans and undrawn commitments | compatible |
| STAGE 3 ACL | CAD 1,204m | CAD 1,050m | Total ECL on loans and undrawn commitments | compatible |
| NON IMPAIRED ACL | CAD 3,779m | CAD 3,820m | Total ECL on loans and undrawn commitments | compatible |
| IMPAIRED ACL | CAD 1,204m | CAD 1,050m | Total ECL on loans and undrawn commitments | compatible |
| TOTAL ACL | CAD 4,983m | CAD 4,870m | Total ECL on loans and undrawn commitments | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
CIBC reports a performing-loan provision reversal in the current quarter versus an expense in the prior quarter, while impaired-loan provisions increased. CIBC attributes higher quarterly impaired PCL mainly to Capital Markets and Canadian Commercial Banking and Wealth Management. CIBC cites Canadian residential mortgages, retail and wholesale, transportation, and U.S.-dollar appreciation as upward GIL drivers, partly offset by declines in real estate and construction, financial institutions, and telecommunications and cable.
Direct explanation
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD -48m | CAD 612m | CAD 564m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -531 | Disclosed component; no causal claim |
| recoveries | +87 | Disclosed component; no causal claim |
| other fx | +33 | Disclosed component; no causal claim |
| interest | -40 | Disclosed component; no causal claim |
| pcl | +564 | Disclosed component; no causal claim |
Loans and off-balance-sheet commitments, excluding debt securities. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
GIL: CAD 4,031m; Comparison unavailable: scope changed
IMPAIRED PCL: CAD 223m; Comparison unavailable: scope changed
IMPAIRED ACL: CAD 1,026m; +90m QoQ
Limitation: NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
Consolidated PCL rose; the current-quarter performing and impaired split is directly disclosed.
GIL: CAD 4,031m; Comparison unavailable: scope changed
IMPAIRED PCL: CAD 223m; Comparison unavailable: scope changed
IMPAIRED ACL: CAD 1,026m; +90m QoQ
Limitation: NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2025-Q4 | CAD 3,712m | Gross impaired carrying amount, all loans in Note 6 | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 4,031m | Gross impaired carrying amount, all loans in Note 6 | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 826m | CAD 827m | Total disclosed ACL on loans and undrawn commitments | compatible |
| STAGE 2 ACL | CAD 780m | CAD 756m | Total disclosed ACL on loans and undrawn commitments | compatible |
| STAGE 3 ACL | CAD 1,026m | CAD 936m | Total disclosed ACL on loans and undrawn commitments | compatible |
| NON IMPAIRED ACL | CAD 1,606m | CAD 1,583m | Total disclosed ACL on loans and undrawn commitments | compatible |
| IMPAIRED ACL | CAD 1,026m | CAD 936m | Total disclosed ACL on loans and undrawn commitments | compatible |
| TOTAL ACL | CAD 2,632m | CAD 2,519m | Total disclosed ACL on loans and undrawn commitments | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
NBC's Q3 discussion describes non-impaired provisions reflecting loan growth and updated macroeconomic scenarios, partly offset by favourable migration.
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD 23m | CAD 223m | CAD 246m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -180 | Disclosed component; no causal claim |
| recoveries | +48 | Disclosed component; no causal claim |
| other fx | +14 | Disclosed component; no causal claim |
| disposals | -6 | Disclosed component; no causal claim |
| pcl | +237 | Disclosed component; no causal claim |
Loans and off-balance-sheet commitments, excluding debt securities. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
GIL: CAD 10,143m; +353m QoQ
IMPAIRED PCL: CAD 979m; +80m QoQ
IMPAIRED ACL: CAD 2,224m; -93m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
GIL and impaired PCL rose while impaired ACL fell.
GIL: CAD 10,143m; +353m QoQ
IMPAIRED PCL: CAD 979m; +80m QoQ
IMPAIRED ACL: CAD 2,224m; -93m QoQ
Limitation: Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2025-Q4 | CAD 8,682m | Loans, acceptances and commitments, credit quality summary | Same disclosed table and scope; no cross-source join. |
| FY2026-Q2 | CAD 9,790m | Loans, acceptances and commitments, credit quality summary | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 10,143m | Loans, acceptances and commitments, credit quality summary | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 1,684m | CAD 1,781m | Total ACL on retail and wholesale loans and commitments | compatible |
| STAGE 2 ACL | CAD 3,858m | CAD 3,706m | Total ACL on retail and wholesale loans and commitments | compatible |
| STAGE 3 ACL | CAD 2,224m | CAD 2,317m | Total ACL on retail and wholesale loans and commitments | compatible |
| NON IMPAIRED ACL | CAD 5,542m | CAD 5,487m | Total ACL on retail and wholesale loans and commitments | compatible |
| IMPAIRED ACL | CAD 2,224m | CAD 2,317m | Total ACL on retail and wholesale loans and commitments | compatible |
| TOTAL ACL | CAD 7,766m | CAD 7,804m | Total ACL on retail and wholesale loans and commitments | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
RBC attributes higher total PCL primarily to Capital Markets, partly offset by releases in Wealth Management versus provisions last quarter. RBC attributes higher impaired-loan PCL primarily to Capital Markets, partly offset by lower Wealth Management provisions. RBC attributes higher GIL primarily to Capital Markets and Wealth Management, partly offset by lower Commercial Banking impaired loans.
Direct explanation
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD 21m | CAD 979m | CAD 1,000m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -1,106 | Disclosed component; no causal claim |
| recoveries | +116 | Disclosed component; no causal claim |
| other fx | -48 | Disclosed component; no causal claim |
| pcl | +1,000 | Disclosed component; no causal claim |
Loans and off-balance-sheet commitments, excluding debt securities. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
GIL: CAD 5,143m; -138m QoQ
IMPAIRED PCL: CAD 865m; -108m QoQ
IMPAIRED ACL: CAD 1,443m; -87m QoQ
Limitation: TD mortgage-geography scope compatibility and sovereign exposure remain unavailable; neither is inferred.
Intentional drilldown into exposure, reserve, portfolio, and management context.
Current-quarter values preserve each disclosed scope.
GIL and impaired PCL fell; Stage 2 ACL increased.
GIL: CAD 5,143m; -138m QoQ
IMPAIRED PCL: CAD 865m; -108m QoQ
IMPAIRED ACL: CAD 1,443m; -87m QoQ
Limitation: TD mortgage-geography scope compatibility and sovereign exposure remain unavailable; neither is inferred.
Lines are not drawn across known scope or presentation breaks.
| Period | GIL | Scope | Continuity |
|---|---|---|---|
| FY2025-Q3 | CAD 5,334m | Personal, business and government impaired loans | Same disclosed table and scope; no cross-source join. |
| FY2026-Q2 | CAD 5,281m | Personal, business and government impaired loans | Same disclosed table and scope; no cross-source join. |
| FY2026-Q3 | CAD 5,143m | Personal, business and government impaired loans | Same disclosed table and scope; no cross-source join. |
Direct disclosed balances only; unsupported ratios remain suppressed.
| Measure | Current | Prior / comparison | Scope | Coverage |
|---|---|---|---|---|
| STAGE 1 ACL | CAD 2,862m | CAD 2,736m | Allowance for loan losses on funded loans only | compatible |
| STAGE 2 ACL | CAD 4,203m | CAD 4,153m | Allowance for loan losses on funded loans only | compatible |
| STAGE 3 ACL | CAD 1,443m | CAD 1,530m | Allowance for loan losses on funded loans only | compatible |
| NON IMPAIRED ACL | CAD 7,065m | CAD 6,889m | Allowance for loan losses on funded loans only | compatible |
| IMPAIRED ACL | CAD 1,443m | CAD 1,530m | Allowance for loan losses on funded loans only | compatible |
| TOTAL ACL | CAD 8,508m | CAD 8,419m | Allowance for loan losses on funded loans only | compatible |
Direct, partial, related, and unavailable evidence remain distinct.
TD attributes lower quarterly impaired PCL largely to business and government lending portfolios. TD reports lower GIL in U.S. Banking, Wholesale Banking and Canadian commercial portfolios, partly offset by Canadian consumer lending.
Direct explanation
Performing and impaired PCL remain separate from allowance and impaired-loan stocks.
| Period | Performing PCL | Impaired PCL | Compatible subtotal | Reconciliation |
|---|---|---|---|---|
| FY2026-Q3 | CAD 52m | CAD 865m | CAD 917m | reconciled |
Beginning, signed movements, ending, calculated ending, and reconciliation status remain visible.
| Movement | Signed amount | Interpretation |
|---|---|---|
| writeoffs | -1,190 | Disclosed component; no causal claim |
| recoveries | +221 | Disclosed component; no causal claim |
| other fx | +156 | Disclosed component; no causal claim |
| disposals | 0 | Disclosed component; no causal claim |
| pcl | +918 | Disclosed component; no causal claim |
Loans and off-balance-sheet commitments, excluding debt securities. Other/FX remains unexplained within this exact bridge perimeter. Arithmetic reconciliation does not establish economic causality. Note PCL is not automatically consolidated statement PCL.
Verified disclosure
Quarterly PCL fell at four banks, but compatible impaired-exposure and reserve signals remained mixed. PCL fell at BMO, Scotiabank, CIBC and TD, and rose at NBC and RBC. RBC GIL rose CAD 353 million and impaired PCL rose CAD 80 million; impaired ACL fell CAD 93 million. CIBC total PCL fell CAD 41 million: performing PCL fell CAD 105 million while impaired PCL rose CAD 64 million. TD GIL fell CAD 138 million and impaired PCL fell CAD 108 million; Stage 2 ACL rose CAD 50 million.
Verified disclosure
Compatible QoQ GIL increases: SCOTIA, CIBC, RBC. NBC's scope-incompatible comparison is excluded, not treated as flat. Raw GIL dollars are not a bank-risk ranking.
Verified disclosure
Compatible QoQ impaired PCL increases: CIBC, RBC. Q3 uses the directly disclosed consolidated split; the approved Q2 split excludes Credigy POCI. No compatible quarter-on-quarter composition comparison is authorized.
Verified disclosure
GIL and impaired PCL fell; Stage 3 ACL increased. BMO attributes the quarterly decline in impaired PCL largely to lower Canadian P&C provisions. This explains impaired PCL, not the allowance stock. BMO attributes the quarterly GIL decline largely to lower impaired loans in Capital Markets. This is management's GIL explanation, not a causal inference from PCL.
Verified disclosure
GIL rose while impaired PCL fell. Scotiabank attributes lower quarterly impaired PCL primarily to the Canadian retail and International corporate portfolios. The explanation is quarter-on-quarter, not the opposite year-on-year movement. Scotiabank attributes higher GIL primarily to currency translation and new formations in Canadian Banking and International retail. Management does not quantify each driver's contribution in this paragraph. Scotiabank links higher impaired-loan ACL to corporate and International retail provisions and currency translation. This funded-loan stock explanation must not be assigned to the broader allowance bridge's Other/FX component.
Verified disclosure
Total PCL fell despite higher impaired PCL and GIL. CIBC reports a performing-loan provision reversal in the current quarter versus an expense in the prior quarter, while impaired-loan provisions increased. The performing reversal includes a better economic outlook and a U.S. commercial real-estate loan-sale reserve release, partly offset by adverse migration; these are not explanations for all GIL movements. CIBC attributes higher quarterly impaired PCL mainly to Capital Markets and Canadian Commercial Banking and Wealth Management. The segment attribution describes impaired PCL, not gross impaired loans. CIBC cites Canadian residential mortgages, retail and wholesale, transportation, and U.S.-dollar appreciation as upward GIL drivers, partly offset by declines in real estate and construction, financial institutions, and telecommunications and cable. The public explanation is descriptive; no sector shares are inferred.
Verified disclosure
Consolidated PCL rose; the current-quarter performing and impaired split is directly disclosed. NBC's Q3 discussion describes non-impaired provisions reflecting loan growth and updated macroeconomic scenarios, partly offset by favourable migration. This year-on-year discussion does not explain the Q2-to-Q3 consolidated movement or validate the narrower note split.
Verified disclosure
GIL and impaired PCL rose while impaired ACL fell. RBC attributes higher total PCL primarily to Capital Markets, partly offset by releases in Wealth Management versus provisions last quarter. Consolidated PCL includes Other PCL separately from loans. RBC attributes higher impaired-loan PCL primarily to Capital Markets, partly offset by lower Wealth Management provisions. This explains loan PCL; it is not a reserve-adequacy conclusion. RBC attributes higher GIL primarily to Capital Markets and Wealth Management, partly offset by lower Commercial Banking impaired loans. Co-movement with impaired PCL does not establish causality between those metrics.
Verified disclosure
GIL and impaired PCL fell; Stage 2 ACL increased. TD attributes lower quarterly impaired PCL largely to business and government lending portfolios. Performing PCL rose, reflecting credit migration and volume growth; overall improvement is not inferred. TD reports lower GIL in U.S. Banking, Wholesale Banking and Canadian commercial portfolios, partly offset by Canadian consumer lending. TD mortgage-geography scope compatibility and sovereign exposure remain unavailable.
Abstained
This release does not establish reserve adequacy, rank bank risk, or predict future losses. It reports scoped disclosures and monitoring priorities only.
Abstained
This release does not establish reserve adequacy, rank bank risk, or predict future losses. It reports scoped disclosures and monitoring priorities only.
Abstained
This release does not establish reserve adequacy, rank bank risk, or predict future losses. It reports scoped disclosures and monitoring priorities only.
Verified disclosure
NBC FY2026 Q3, three months ended July 31, 2026: consolidated PCL is CAD 23m performing / 223m impaired / 246m total (23 + 223 = 246). Separately, the loans-and-undrawn note scope is CAD 21m performing / 216m impaired / 237m subtotal. These scopes are neither added nor netted. Q3 uses the directly disclosed consolidated split; the approved Q2 split excludes Credigy POCI. No compatible quarter-on-quarter composition comparison is authorized.
Verified disclosure
Bank of Montreal: Watch. Scotiabank: Watch. CIBC: Elevated attention. National Bank of Canada: Watch. Royal Bank of Canada: Routine. TD Bank Group: Watch. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Bank of Montreal: Watch. GIL and impaired PCL fell; Stage 3 ACL increased. GIL: CAD 6,803m; -136m QoQ. IMPAIRED PCL: CAD 708m; -26m QoQ. IMPAIRED ACL: CAD 1,268m; +107m QoQ. Inspect business-and-government formations alongside the reported Capital Markets GIL decline. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Performing CAD 14m; impaired CAD 708m. Total PCL composition Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
Bank of Montreal: FY2026-Q3 GIL 6803 CAD millions; point in time; Gross loans and acceptances. Bank of Montreal: FY2026-Q2 GIL 6939 CAD millions; point in time; consolidated_funded_loans_and_acceptances.
Verified disclosure
Bank of Montreal: FY2026-Q3 impaired PCL 708 CAD millions; three months; Total PCL composition. Bank of Montreal: FY2026-Q2 impaired PCL 734 CAD millions; three months; Total PCL composition.
Verified disclosure
Bank of Montreal: FY2026-Q3 performing PCL 14 CAD millions; three months; Total PCL composition. Bank of Montreal: FY2026-Q2 performing PCL 5 CAD millions; three months; Total PCL composition.
Verified disclosure
Bank of Montreal: FY2026-Q3 Stage 2 ACL 3288 CAD millions; point in time; Total ACL on loans and other credit instruments. Bank of Montreal: FY2026-Q2 Stage 2 ACL 3259 CAD millions; point in time; Total ACL on loans and other credit instruments.
Verified disclosure
Bank of Montreal: FY2026-Q3 Stage 3 ACL 1268 CAD millions; point in time; Total ACL on loans and other credit instruments. Bank of Montreal: FY2026-Q2 Stage 3 ACL 1161 CAD millions; point in time; Total ACL on loans and other credit instruments.
Verified disclosure
Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
Scotiabank: Watch. GIL rose while impaired PCL fell. GIL: CAD 7,801m; +193m QoQ. IMPAIRED PCL: CAD 1,018m; -111m QoQ. IMPAIRED ACL: CAD 2,498m; +90m QoQ. Separate currency translation from new impaired formations before interpreting the GIL increase. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Performing CAD 61m; impaired CAD 1,018m. Total PCL composition Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
Scotiabank: FY2026-Q3 GIL 7801 CAD millions; point in time; Gross loans and acceptances. Scotiabank: FY2026-Q2 GIL 7608 CAD millions; point in time; consolidated_funded_loans_and_acceptances.
Verified disclosure
Scotiabank: FY2026-Q3 impaired PCL 1018 CAD millions; three months; Total PCL composition. Scotiabank: FY2026-Q2 impaired PCL 1129 CAD millions; three months; Bank-presented total PCL composition.
Verified disclosure
Scotiabank: FY2026-Q3 performing PCL 61 CAD millions; three months; Total PCL composition. Scotiabank: FY2026-Q2 performing PCL 88 CAD millions; three months; Bank-presented total PCL composition.
Verified disclosure
Scotiabank: FY2026-Q3 Stage 2 ACL 3048 CAD millions; point in time; ACL on funded loans only. Scotiabank: FY2026-Q2 Stage 2 ACL 3040 CAD millions; point in time; ACL on funded loans only.
Verified disclosure
Scotiabank: FY2026-Q3 Stage 3 ACL 2498 CAD millions; point in time; ACL on funded loans only. Scotiabank: FY2026-Q2 Stage 3 ACL 2408 CAD millions; point in time; ACL on funded loans only.
Verified disclosure
Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
CIBC: Elevated attention. Total PCL fell despite higher impaired PCL and GIL. GIL: CAD 4,024m; +57m QoQ. IMPAIRED PCL: CAD 612m; +64m QoQ. IMPAIRED ACL: CAD 1,204m; +154m QoQ. Track whether higher impaired PCL persists after the performing-provision reversal. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Performing CAD -48m; impaired CAD 612m. Total PCL composition Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
CIBC: FY2026-Q3 GIL 4024 CAD millions; point in time; Impaired loans, consumer and business/government. CIBC: FY2026-Q2 GIL 3967 CAD millions; point in time; incompatible_net_schedule.
Verified disclosure
CIBC: FY2026-Q3 impaired PCL 612 CAD millions; three months; Total PCL composition. CIBC: FY2026-Q2 impaired PCL 548 CAD millions; three months; Total PCL composition.
Verified disclosure
CIBC: FY2026-Q3 performing PCL -48 CAD millions; three months; Total PCL composition. CIBC: FY2026-Q2 performing PCL 57 CAD millions; three months; Total PCL composition.
Verified disclosure
CIBC: FY2026-Q3 Stage 2 ACL 2699 CAD millions; point in time; Total ECL on loans and undrawn commitments. CIBC: FY2026-Q2 Stage 2 ACL 2782 CAD millions; point in time; Total ECL on loans and undrawn commitments.
Verified disclosure
CIBC: FY2026-Q3 Stage 3 ACL 1204 CAD millions; point in time; Total ECL on loans and undrawn commitments. CIBC: FY2026-Q2 Stage 3 ACL 1050 CAD millions; point in time; Total ECL on loans and undrawn commitments.
Verified disclosure
Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
National Bank of Canada: Watch. Consolidated PCL rose; the current-quarter performing and impaired split is directly disclosed. GIL: CAD 4,031m; Comparison unavailable: scope changed. IMPAIRED PCL: CAD 223m; Comparison unavailable: scope changed. IMPAIRED ACL: CAD 1,026m; +90m QoQ. Confirm a compatible prior consolidated split before interpreting composition changes; retain the separate loans-and-undrawn note scope. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
National Bank of Canada, FY2026-Q3: performing PCL CAD 23m; impaired PCL CAD 223m; consolidated PCL CAD 246m. Consolidated PCL. NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Verified disclosure
National Bank of Canada: FY2026-Q3 GIL 4031 CAD millions; point in time; Gross impaired carrying amount, all loans in Note 6. GIL: CAD 4,031m; Comparison unavailable: scope changed.
Verified disclosure
National Bank of Canada: FY2026-Q3 impaired PCL 223 CAD millions; three months; Consolidated PCL. NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Verified disclosure
National Bank of Canada: FY2026-Q3 performing PCL 23 CAD millions; three months; Consolidated PCL. NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Verified disclosure
National Bank of Canada: FY2026-Q3 Stage 2 ACL 780 CAD millions; point in time; Total disclosed ACL on loans and undrawn commitments. National Bank of Canada: FY2026-Q2 Stage 2 ACL 756 CAD millions; point in time; Total disclosed ACL on loans and undrawn commitments.
Verified disclosure
National Bank of Canada: FY2026-Q3 Stage 3 ACL 1026 CAD millions; point in time; Total disclosed ACL on loans and undrawn commitments. National Bank of Canada: FY2026-Q2 Stage 3 ACL 936 CAD millions; point in time; Total disclosed ACL on loans and undrawn commitments.
Verified disclosure
NBC's consolidated PCL and loans-and-undrawn note split are separate valid scopes, not additive or netted. Consolidated composition is not compared with the prior POCI-excluded split. No category is assigned between these scopes.
Verified disclosure
Royal Bank of Canada: Routine. GIL and impaired PCL rose while impaired ACL fell. GIL: CAD 10,143m; +353m QoQ. IMPAIRED PCL: CAD 979m; +80m QoQ. IMPAIRED ACL: CAD 2,224m; -93m QoQ. Inspect Capital Markets impaired exposures alongside lower impaired ACL; do not infer reserve inadequacy. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Performing CAD 21m; impaired CAD 979m. Loans PCL excluding Other PCL Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
Royal Bank of Canada: FY2026-Q3 GIL 10143 CAD millions; point in time; Loans, acceptances and commitments, credit quality summary. Royal Bank of Canada: FY2026-Q2 GIL 9790 CAD millions; point in time; consolidated_funded_loans_and_acceptances.
Verified disclosure
Royal Bank of Canada: FY2026-Q3 impaired PCL 979 CAD millions; three months; Loans PCL excluding Other PCL. Royal Bank of Canada: FY2026-Q2 impaired PCL 899 CAD millions; three months; Loan PCL composition.
Verified disclosure
Royal Bank of Canada: FY2026-Q3 performing PCL 21 CAD millions; three months; Loans PCL excluding Other PCL. Royal Bank of Canada: FY2026-Q2 performing PCL 18 CAD millions; three months; Loan PCL composition.
Verified disclosure
Royal Bank of Canada: FY2026-Q3 Stage 2 ACL 3858 CAD millions; point in time; Total ACL on retail and wholesale loans and commitments. Royal Bank of Canada: FY2026-Q2 Stage 2 ACL 3706 CAD millions; point in time; Total ACL on retail and wholesale loans and commitments.
Verified disclosure
Royal Bank of Canada: FY2026-Q3 Stage 3 ACL 2224 CAD millions; point in time; Total ACL on retail and wholesale loans and commitments. Royal Bank of Canada: FY2026-Q2 Stage 3 ACL 2317 CAD millions; point in time; Total ACL on retail and wholesale loans and commitments.
Verified disclosure
Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.
Verified disclosure
TD Bank Group: Watch. GIL and impaired PCL fell; Stage 2 ACL increased. GIL: CAD 5,143m; -138m QoQ. IMPAIRED PCL: CAD 865m; -108m QoQ. IMPAIRED ACL: CAD 1,443m; -87m QoQ. Follow Canadian consumer migration while retaining the mortgage-geography and sovereign-exposure limitations. Routine, Watch and Elevated attention are monitoring priorities, not ratings or rankings. Missing comparisons limit the assessment.
Verified disclosure
Performing CAD 52m; impaired CAD 865m. Total PCL composition TD mortgage-geography scope compatibility and sovereign exposure remain unavailable; neither is inferred.
Verified disclosure
TD Bank Group: FY2026-Q3 GIL 5143 CAD millions; point in time; Personal, business and government impaired loans. TD Bank Group: FY2026-Q2 GIL 5281 CAD millions; point in time; consolidated_funded_loans_and_acceptances.
Verified disclosure
TD Bank Group: FY2026-Q3 impaired PCL 865 CAD millions; three months; Total PCL composition. TD Bank Group: FY2026-Q2 impaired PCL 973 CAD millions; three months; Total PCL composition.
Verified disclosure
TD Bank Group: FY2026-Q3 performing PCL 52 CAD millions; three months; Total PCL composition. TD Bank Group: FY2026-Q2 performing PCL 28 CAD millions; three months; Total PCL composition.
Verified disclosure
TD Bank Group: FY2026-Q3 Stage 2 ACL 4203 CAD millions; point in time; Allowance for loan losses on funded loans only. TD Bank Group: FY2026-Q2 Stage 2 ACL 4153 CAD millions; point in time; Allowance for loan losses on funded loans only.
Verified disclosure
TD Bank Group: FY2026-Q3 Stage 3 ACL 1443 CAD millions; point in time; Allowance for loan losses on funded loans only. TD Bank Group: FY2026-Q2 Stage 3 ACL 1530 CAD millions; point in time; Allowance for loan losses on funded loans only.
Verified disclosure
TD mortgage-geography scope compatibility and sovereign exposure remain unavailable; neither is inferred.
Verified disclosure
CAD millions; quarterly flows and ending stocks remain distinct. Comparisons require reviewed scope and duration, not matching metric names. QoQ percentage change in consolidated statement PCL. Each bank's own approved FY2026 Q2 consolidated PCL; not gross loans Allowance scopes differ across banks. Funded-only and commitments-inclusive stage balances are not a common peer ratio denominator.